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Costs of medical care for
mesothelioma
Eric Borrelli , Zachary Babcock and Stephen Kogut

Abstract
Malignant mesothelioma is a rare and devastating form of cancer with an increasing economic burden. We sought to
describe the direct cost burden of mesothelioma to the US health system. A systematic literature review was performed to
locate published estimates of the medical cost of mesothelioma. In addition, we performed an analysis of hospital discharge
data from the National Inpatient Sample, Healthcare Cost and Utilization Project, Agency for Healthcare Research and
Quality. We also reviewed publicly available legal settlements. We found that published estimates of the cost of medical
care for mesothelioma are sparse, and differ with respect to nation, timeframe, and types of cost included. For the year
2014 in the United States, we estimated a mean cost per mesothelioma hospitalization of US$24,124 (95% confidence
interval: US$20,819–US$28,983) and a total cost for hospital care of US$44,214,835. In conclusion, we found that reports
describing the direct medical cost of care for mesothelioma in the United States are lacking, yet the per-patient cost of care
is substantial, as evidenced by analyses of inpatient care and legal settlements.
Keywords
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Introduction
Mesothelioma is a rare and fatal form of cancer that is linked
to occupational exposure to asbestos. The disease arises from
the mesothelial cells of the pleura, but can also occur in the
pericardium, peritoneum, and tunica vaginalis testis.1,2
Asbestos mining and use in the United States peaked in 1973
and started to decline over the next two decades.3 Mining of
asbestos finally ended in the United States in 2002.3
Approximately 2,750 mesothelioma deaths occurred
annually in the United States during 2011–2015.4 Roughly
80% of these deaths were among males, and approximately
95% were Caucasians.4 The prevalence of mesothelioma in
the United States is estimated to have peaked around 2007,
and is projected to decline over the next several decades.5,6
Mesothelioma has a very poor prognosis. The latency
between development of mesothelioma after exposure to

asbestos ranges from 20 to 50 years, but some cases occur
as late as 70 years after.3,7,8 A higher intensity of exposure is
associated with a shorter latency period.9 The median age
of diagnosis for mesothelioma is approximately 72 years.10,11
Patients with mesothelioma have a mean survival of
approximately 1 year after diagnosis.10,11 Diagnosis is often
made at an advanced stage, which is reflected in the low
survival rates.12 While a small subgroup of patients may
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survive for many years beyond diagnosis, for most patients,
the prognosis is bleak with only limited treatment options
available to mitigate the cancer.
Treatment options generally depend upon the patient’s
clinical status and prognosis upon being diagnosed. Firstline chemotherapy includes different combinations and
regimens of the following chemotherapy agents: pemetrexed, cisplatin, bevacizumab, carboplatin, gemcitabine,
or vinorelbine.11 For patients who are suitable candidates,
surgical procedures might include pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP).11,13
Patients who receive either P/D or EPP are also recommended to have a mediastinal node dissection.11 Radiation
therapy may also be used in patients postoperatively after
EPP, for palliative care, or as prophylaxis to prevent surgical tract recurrence.11 Due to the advanced stage of disease at diagnosis, treatment options, which are often very
costly, include extensive surgery, systemic therapy, and
radiation therapy.
Given the long latency period of the disease, mesothelioma cases will continue to develop in the United
States over the next several decades, adding to the cost
burden of cancer care overall. Published data regarding
the direct medical costs of mesothelioma in the United
States are lacking. The objective of this study was to
describe the direct cost burden of mesothelioma to the
US health system.

Material and methods
Literature review
A systematic literature search was performed using PubMed
and Embase, the International Society for Pharmaco‑
economics and Outcomes Research (ISPOR) scientific
presentation database, and the International Pharmaceutical
Abstracts (IPA) database to locate published estimates of the
cost of mesothelioma in the United States and throughout
the world. The review of PubMed and Embase consisted of
the search term “mesothelioma AND cost.” The review of
the ISPOR scientific presentation database consisted of the
search term “mesothelioma” in abstracts. The review of the
IPA database consisted of the search terms “mesothelioma
AND cost.” Articles and presentations that only discussed
the cost of specific medications, chemotherapy, or surgery
were excluded.

Inpatient cost burden
We analyzed the National Inpatient Sample (NIS),
Healthcare Cost and Utilization Project (HCUP; US Agency
for Healthcare Research and Quality) for the year of 2014
using the International Classification of Diseases, 9th
Revision (ICD-9) diagnosis codes of 163.0 (malignant neoplasm of parietal pleura), 163.1 (malignant neoplasm of
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visceral pleura), 163.8 (malignant neoplasm of other specified sites of pleura), and 163.9 (malignant neoplasm of
pleura unspecified).14 We determined overall and mean
costs and mean length of stay for hospitalizations having a
primary diagnosis of mesothelioma, overall and according
to patient demographics. We also evaluated the cost of procedures performed during a hospital stay, which included
32.30 video-assisted thoracic surgery (VATS), 32.50 EPP,
34.51 P/D, 33.20 thoracoscopic biopsy, 34.20 thoracoscopic pleural biopsy, and 34.91 thoracentesis.

Cost of chemotherapy
The cost of chemotherapy was estimated for two common
first-line chemotherapy regimens, as recommended by the
National Comprehensive Cancer Network Clinical Practice
Guidelines in Oncology (NCCN Guidelines) for malignant
pleural mesothelioma.11 The first chemotherapy regimen
considered was pemetrexed 500 mg/m2 on day 1, plus cisplatin 75 mg/m2 on day 1, administered every 3 weeks. The
second chemotherapy regimen considered was both drugs
and dosages included in the first regimen plus bevacizumab
15 mg/kg administered on day 1, administered every
3 weeks. The cost of chemotherapy was calculated using
the wholesale acquisition cost (WAC) for 2017.15 Dosing
was calculated using a patient weight of 72 kg and a body
surface area (BSA) of 2 m2 which assumed a typical BSA
for a male cancer patient of 1.91 m2 and rounding up to
account for non-used chemotherapy from open vials which
must be discarded.16 Costs were reported in 2017 dollars.

LexisNexis academic review
To supplement our analyses of direct medical costs, we also
reviewed published settlements from mesothelioma legal
cases in the United States, using the cataloging resource
LexisNexis Academic to find legal settlements and lawsuits
where the total estimated direct cost of care for mesothelioma was reported. Our query consisted of three different
search terms: “mesothelioma,” “mesothelioma treatment
costs,” and “mesothelioma medical expenses.” For the legal
settlements and lawsuits identified, we only considered the
amount of monetary award that was specifically for medical
expenses and omitted amounts for non-medical damages.

Results
The systematic literature review of PubMed returned 167 hits
for the search terms “mesothelioma AND cost,” with five
studies meeting our inclusion criteria.17–21 The review of the
ISPOR scientific presentation database returned 11 matches
for the search term “mesothelioma” of which two were applicable.22,23 The review of the IPA database returned six matches
for the search terms “mesothelioma AND cost,” but none
were applicable. The review of Embase returned 349 matches,
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and two additional results were applicable.24,25 In total, we
identified nine relevant articles, abstracts, and presentations
regarding the direct medical cost of mesothelioma.
We identified 1 abstract which addressed the cost of
mesothelioma-related care by Babcock et al. which examined overall and per episode costs for mesothelioma for the
inpatient setting in the United States during 2012.23 They
reported an aggregate US hospital cost of US$50,473,622,
and a mean per-episode cost of US$25,566, which differed
for hospitalizations involving a major procedure (mean
cost of US$30,734) versus those without a major procedure (US$13,493).23
We identified several other cost of illness studies conducted in other nations. Zocchetti examined the annual economic impact in Italy where the average pleural
mesothelioma case costs approximately €67,000 overall,
with €37,000 spent on medication.18 Serrier et al. described
the social cost of occupational respiratory cancers in France
during 2010, reporting an average annual direct cost per
patient for mesothelioma of €33,422 overall,19 of which
€19,500 was for hospital care.
Gomez et al. examined direct medical cost for jobrelated cancers in Spain in 2008,20 finding that total annual
hospital costs for males with mesothelioma were €498,110,
and total hospital costs for females were €66,766. Cost per
hospitalization, however, was similar between males and
females (€6,731 vs €6,676). Among cost components, specialized care costs accounted for €566,292, primary care
costs were €20,386, pharmacy costs were €294,472, and
the overall annual sanitary cost for mesothelioma was
€881,150.56.20 Lee et al. estimated the financial savings of
preventing occupational cancer from the perspective of the
Taiwanese health system during 1997–2005, finding that
averting a case of mesothelioma would yield an average
lifetime cost savings of US$14,900.17 Soeberg et al.25 found
that direct medical costs in Taiwan were approximately
US$18,812 following a diagnosis of malignant pleural
mesothelioma; whereas the direct medical costs in Australia
were approximately US$20,573.25 Watterson et al.21
reported mesothelioma costs in Scotland for the year 2000
as £942,038, with inpatient care accounting for £906,965
and day cases accounting for £35,073 of total spending.
Tournier et al.22 estimated malignant pleural mesothelioma
costs in France for 2011 and 2012, finding that the total cost
during these 2 years was €52,000,000, with medications
comprising 31% of total cost, while diagnosis-related group
tariffs represented 66% of total expenditure, with a mean
cost per patient of €27,624.22
Ak et al. determined the lifetime cost by treatment regimen and prognosis for patients with malignant pleural mesothelioma in Turkey during 2005–2014.24 The average cost
for patients who received basic supportive care was
US$1,355 while the average cost for patients who received
only chemotherapy was US$6,595.24 The average cost for
patients who received both chemotherapy and radiation
was US$8,962.24 For patients receiving P/D, chemotherapy,
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and radiation the average cost was US$11,691, while mean
cost for patients receiving EPP, chemotherapy, and radiation was US$13,788.24
Our analysis of the 2014 NIS identified 1,675 hospital
discharges in the United States having a primary diagnosis of mesothelioma (Table 1). The estimated aggregate
US hospital inpatient cost associated with a primary diagnosis of mesothelioma in 2014 was US$41,709,687. The
mean cost per hospitalization was US$24,901 (95% confidence interval (CI): US$20,819–US$28,983) and the
mean length of stay was 7.7 days (95% CI: 7.0–8.4). The
Northeast had the highest mean cost per region at
US$33,396 per episode (95% CI: US$23,045–US$43,748),
and the Midwest had the lowest mean cost of US$18,206
per episode (95% CI: US$15,523–US$20,888). Patients
aged 65–84 years comprised two-thirds of the discharges.
Patients 45-64 years of age incurred the highest mean cost
per episode (US$30,845; 95% CI: US$22,431–
US$39,258), while the lowest mean cost per episode was
among patients aged 85 years and older (US$15,534; 95%
CI: US$12,717–US$18,352). Mean cost per episode was
similar among Medicare, private, and other insurance
types; except for Medicaid which accounted for a lesser
number of cases (n = 60) and a lower mean cost per episode (US$18,754; 95% CI: US$14,803–US$22,706). The
mean cost per episode was substantially greater among
hospitalizations associated with a mesothelioma-related
procedure (Table 1) (US$29,344; 95% CI: US$24,349–
US$34,340), as compared with hospitalizations where
such procedures were not performed (US$10,263; 95%
CI: US$8579– US$11,946). The mean cost per procedure
ranged from US$16,089 for drainage of pleural cavity
(95% CI: US$12,883–US$19,296) to US$62,408 for
pneumonectomy, NOS (95% CI: US$48,385–US$76,431).
Higher mean costs per stay were generally associated with
longer lengths of stay (Table 2).
The cost of chemotherapy was estimated considering a
first-line regimen with pemetrexed plus cisplatin for six
cycles with standard dosing per NCCN guidelines,11 assuming a male patient weighing 72 kg and having a BSA of
1.91 m2 (Table 3). Drug costs were derived from published
WAC for 2017. Given these assumptions, the total cost of
chemotherapy was estimated as US$38,779. If the patient
also received bevacizumab (as recommended for unresectable disease),11 the chemotherapy regimen cost would
increase to US$87,741. These figures do not include facility costs or management of toxicity.
Our review of LexisNexis Academic returned 20 relevant legal cases describing monetary awards associated
with mesothelioma (Table 4). Of these cases, 18 patients
had careers that exposed them to asbestos while 2 had
secondary exposure. In reviewing these reports, we were
often unable to distinguish cost of care provided from
patient out-of-pocket expenditures. Six of the cases
included monetary awards to the patient for future medical expenses while 19 of the 20 cases detailed monetary

4

Rare Tumors

Table 1. Mean and total hospital expenditures for mesothelioma in the United States, 2014.
Patient
demographics

Discharges, weighted
n (%)

Total expenditures
(US$)

Mean cost US$ (95% CI)

Mean length of stay in days
(95% CI)

Overall
Gender
Male
Female
Race
White
Black
Hispanic
Other
Age (years)
0–44
45–64
65–84
85+
Payer
Medicare
Medicaid
Private
Other
Region
Northeast
Midwest
South
West
Procedure
No
Yes

1,675

41,709,687

24,901 (20,819–28,983)

7.7 (7.0–8.4)

1,215 (72.5)
460 (27.5)

30,912,622
10,797,065

25,442 (21,804–29,801)
23,472 (18,627–28,317)

7.9 (7.1–8.7)
7.3 (6.2–8.3)

1,350 (80.6)
85 (5.1)
80 (4.8)
160 (9.6)

34,246,670
1,894,533
1,550,377
4,018,107

25,368 (20,557–30,179)
22,289 (13,291–31,286)
19,380 (15,088–23,671)
25,113 (20,183–30,043)

7.7 (6.9–8.5)
8.6 (5.0–12.2)
8.7 (6.1–11.3)
7.0 (5.7–8.2)

50 (3)
335 (20)
1,115 (66.6)
175 (10.4)

1,111,422
10,332,995
27,546,763
2,718,507

22,228 (12,777–31,679)
30,845 (22,431–39,258)
24,706 (20,488–28,924)
15,534 (12,717–18,352)

5.6 (3.9–7.3)
9.0 (7.5–10.4)
7.6 (6.7–8.4)
7.1 (5.8–8.5)

1,160 (69.3)
60 (3.6)
390 (23.3)
65 (3.9)

29,090,012
1,125,263
9,849,751
1,644,661

25,078 (20,648–29,507)
18,754 (14,803–22,706)
25,256 (18,858–31,653)
25,302 (17,866–32,739)

7.7 (6.8–8.6)
9.4 (7.5–11.3)
7.1 (6.0–8.1)
10.0 (7.6–12.4)

505 (30.1)
330 (19.7)
550 (32.8)
290 (17.3)

16,865,165
6,007,949
11,596,119
7,240,454

33,396 (23,045–43,748)
18,206 (15,523–20,888)
21,084 (16,161–26,006)
24,967 (19,279–30,655)

8.6 (6.8–10.4)
6.8 (5.8–7.8)
8.3 (7.2–9.4)
6.3 (5.4–7.3)

390 (23.3)
1,285 (76.7)

4,002,436
37,707,251

10,263 (8,579–11,946)
29,344 (24,349–34,340)

5.1 (4.4–5.8)
8.5 (7.7–9.4)

CI: confidence interval.

Table 2. Mean hospital cost and LOS for mesothelioma-specific medical procedures in the United States, 2014.
Surgery/procedure

ICD-9
procedure code

n (%)

Mean cost US$ (95% CI)

LOS mean (days; 95% CI)

Thoracoscopic pleural biopsy
Thoracentesis
Pleurectomy/decortication
Other excision of pleura
Drainage of pleural cavity
Pneumonectomy, NOS
Thoracoscopic decortication
Other procedure

34.2
34.91
34.51
34.59
34.06
32.59
34.52
–

460
295
170
145
125
40
40
385

16,575 (14,361–18,790)
19,899 (17,366–22,431)
53,993 (43,092–64,893)
46,217 (30,456–61,978)
16,089 (12,883–19,296)
62,408 (48,385–76,431)
46,873 (2,568–91,177)
15,095 (10.601–19,588)

5.4 (4.7–6.2)
9.5 (8.3–10.6)
12.6 (10.7–14.4)
10.7 (7.7–13.7)
6.3 (4.8–7.8)
11.2 (7.8–14.7)
11.1 (0.7–21.5)
5.9 (4.8–7.0)

LOS: length of stay; ICD-9: International Classification of Diseases, 9th Revision; CI: confidence interval.

awards for past medical expenses. The monetary awards
for total medical expenses ranged from US$113,594 to
US$900,000.

Discussion
Mesothelioma is a rare yet costly disease. However, data
describing the direct costs of care in the United States for the

treatment of mesothelioma are lacking, while recent reports
from other countries are also scant. A study of the cost of
mesothelioma in Italy during 2002–2015 estimated the per
patient cost to be €67,000 euros (approximately US$73,700
in 2015 dollars). The average annual per patient cost burden
of mesothelioma in France was estimated at €33,422
(approximately US US$40,899 in 2010 dollars).20 These
reports suggest that the cost of care for mesothelioma is
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Table 3. Cost of typical chemotherapy regimen for mesothelioma.
Medication

Dosinga

Cost (WAC) per cycle, US$

Total cost (6 cycles), US$

Pemetrexed
Cisplatin
(+/–) Bevacizumab
Total (A + B)
Total (A + B + C)

500 mg/m²
75 mg/m2
15 mg/kg day 1

6,406.20
51.00
8,160.35

38,473
306
48,962
38,779
87,741

WAC: wholesale acquisition cost; BSA: body surface area.
aAssumes patient weight of 72 kg and a BSA of 1.91 m2.

comparable to costs of care for other respiratory cancers.
For example, annual costs of initial care for lung cancer
have been estimated at US$72,639 among non-senior adults
(2010 dollars).26 Patients with mesothelioma who undergo
surgical procedures incur higher costs of care. For such
patients, in our analysis we estimated an average annual cost
of inpatient care of US$29,344 for 2014. Data from the US
Medicare population indicate that approximately 30% of
mesothelioma patients underwent a surgical procedure during 2005–2009.27 Although surgical options are listed as a
treatment option in current guidelines, the data related to the
impact of surgery on health outcome is limited.11 Taking this
into account in combination with the high cost of care for
surgical procedures, future studies might assess the cost
effectiveness of these options. Radiation therapy may also
be utilized in patients with mesothelioma. An analysis of
data from the Medicare Surveillance, Epidemiology, and
End Results (SEER) program reported a median cost of
approximately US$9,000 (in 2009 dollars) per course for a
typical patient with lung cancer.28
Our analysis of the NIS yielded an estimated total annual
hospital cost for mesothelioma of US$41,709,687, representing 1,675 care episodes during 2014. Medicare was
responsible for approximately 70% of these inpatient costs,
given the predominance of diagnosis at older age. Inpatient
costs for those age 85 years and older were substantially
lower than for other age groups, which may be potentially
due to less aggressive care and surgery being provided to
older patients. These figures represent a small fraction of the
total annual inpatient expenditure for lung malignancies,
which totaled US$2,161,540,025 for 2014 (n = 123,365
inpatient episodes).14 Despite its small contribution to the
total cost of care for all lung malignancies, the per patient
annual costs for mesothelioma care are on par with other
cancer types and pose substantial cost burden on health
plans. It is important to note that hospital discharges should
not be interpreted as a true incidence rate, as a patient may
experience multiple inpatient episodes in a given year.
Medications also contribute substantially to the cost
burden of mesothelioma. We estimated the average
direct medication cost for recommended chemotherapy
for a typical male patient receiving 6 cycles. For patients
with unresectable disease, adding bevacizumab to the
regimen more than doubled the total medication cost,

yielding an average estimated expense of US$87,741
per patient (2017 dollars). Continuing maintenance therapy with bevacizumab increased treatment cost by an
estimated US$8,160 per month. In one trial, the addition
of bevacizumab to pemetrexed/cisplatin increased overall survival by nearly 3 months.29 Cost-effectiveness
studies evaluating the value of bevacizumab in combination with pemetrexed/cisplatin or as maintenance
therapy from the US payer perspective are lacking. One
analysis determined that the routine addition of bevacizumab was not a cost-effective alternative in China.30
While treatment advances are critically needed given
the limitations of existing chemotherapeutic options, new
agents will likely significantly increase per-patient medical costs. Outpatient medication costs for palliation and
side-effect management are typically less consequential
given the availability of relatively inexpensive generic
formulations of vitamins, corticosteroids, and pain
medications.
We were unable to locate any published data detailing
the end-of-life costs for mesothelioma specifically.
Zuckerman et al. determined the end-of-life costs for lung
cancer, which can be applied as a best available comparator. Depending on the extent of use of hospice services and
nursing home care, the mean total spending for end-of-life
costs in lung cancer were estimated to range from
US$44,504 to US$57,811.31
Additional inferences regarding the total lifetime
medical cost burden of mesothelioma might be drawn
from examining awards associated with legal settlements. In researching publicly available records of mesothelioma-related lawsuits, we identified monetary
awards for medical expenses ranging from US$113,595
to US$900,000. These figures are within the range of the
costs we estimated for inpatient care and chemotherapy
combined. Although these legal awards identified the
portion of the total award specifically attributed to medical expenses, details regarding how these amounts were
calculated were generally not provided. Litigation for
mesothelioma is expected to continue as cases arise during the next several decades. The overall cost of litigation claims are projected to range between US$200 and
US$265 billion after all cases are settled in the United
States.32
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Table 4. Example monetary awards for mesothelioma cases.
Occupation

Total award for medical
expenses (US$)

Case

Flooring installer

113,594.25

Plumber

114,208.00

Aluminum worker

147,153.53

Maintained boilers
and turbines

162,995.48

Grandfather was
union insulatora,b
Sales engineer of
chemicals

170,575.00

Plumber and
pipefitter

255,000.00

US Navy

319,650.00

Janitora

325,000.00

Sheet metal
workera

325,369.32

Laundry pad
workera

350,000.00

Construction
workera

360,000.00

Navy ship worker

394,857.01

Pipefitter and
weldera
Ship worker

402,449.28

Ship worker
Sheet metal
worker
US Navy and
boiler technician

450,000.00
467,672.37

Romana I. Olivotto, Widow of Joe Olivotto, Appellee AND Cross-Appellant v.
Demarco Brothers Company, Appellant AND Cross-Appellant, Supreme Court
of Nebraska, 2007
Maria Elena Luna, Carmel L. Bass, Jusin M. Luna, and Maria Theresa Gabriella
Alphonse, Individually and on Behalf of Late Rafael Medardo Luna v. A.W.
Chesterton Company, et al., Court of Appeal of Louisiana, First Circuit, 2014
Sandra Blackburn et al. v. Employers Insurance of Wausau, Supreme Court of
Tennessee, Special Workers’ Compensation Appeals Panel, at Nashville, 2008
Dorothy Carter White, Lucy White, Tommy Lloyd White, Jr., Frederick White,
and William White v. Entegry Gulf States Louisiana, L.L.C., Eagle Incorporated,
Taylorseidenbach, Inc., The J. Graves Insulation Company, Inc., Union Carbide
Corporation, and XYZ Insurance Company, Court of Appeal of Louisiana, First
Circuit, 2014
Georgia-Pacific, LLC F/K/A Georgia-Pacific Corporation v. Jocelyn Anne Farrar,
Court of Special Appeals of Maryland, 2012
John M. Nolen et al., Plaintiffs and Respondents, v. Foster Wheeler Energy
Corp., Defendant and Appellant, Court of Appeal of California, Second Appellate
District, Division Two, 2012
Patricia Case, Plaintiff and Appellant, v. Kaiser Gypsum Company, Inc., Defendant
and Appellant, Court of Appeal of California, First Appellate District, Division
Four, 2016
John Crane, Inc. v. Margaret Diane Hardick, Executor of the Estate of Robert
Eugene Hardick, Deceased, et al., Supreme Court of Virginia, 2012
Bobby Evans, as successor-in-interest, et al., Plaintiffs and Appellants, v.
Certaineed Corporation, Defendant, and Cross-Appellant; LOS Angeles
Department of Water and Power, Defendant and Cross-Respondent, Court of
Appeal of California, Second Appellate District, Division Eight, 2012
Genaro Garcia et al., Plaintiffs and Appellants, v. Duro Dyne Corporation,
Defendant and Appellant, Court of Appeal of California, First Appellate District,
Division One, 2007
John T. Ward et al., Plaintiffs and Respondents, v. Goss-Jewett Co. of Northern
California, Defendant and Appellant, Court of Appeal of California, First
Appellate District, Division Three, 2014
Joan Mahoney et al., Plaintiffs and Respondents, v. Georgia-Pacific, LLC,
Defendant and Appellant, Court of Appeal of California, First Appellate District,
Division One, 2009
John Crane Inc. v. Wanda T. Jones, Administratrix, of the Estate of Garland F.
Jones Jr. Supreme Court of Virginia, 2007
Ray F. Rando Versus Anco Insulations, Inc., et al., Court of Appeal of Louisiana,
First Circuit, 2008
Exon Mobil Corporation v. Connie Minton, Executor of the State of Rubert E
Minton. Supreme Court of Virginia, 2013
George Parker v. John Crane Inc., Newport News Circuit Court, 2016
Scapa Dryer Fabrics, Inc., v. Knight et al., Court of Appeals of Georgia, 2015

Wife of nuclear
plant workerb

547,008.93

Vehicle
serviceman/
mechanic

900,000.00

aRepresents
bSecondary

225,000.00

430,963.70

545,703.29

Anne Pfieffer, Individually and as Personal Representative, etc., Plaintiff and
Appellant, v. John Crane, Inc., Defendant and Appellant, Court of Appeal of
California, Second Appellate District, Division Four, 2013
Melissa Ann Bobo and Shannon Jean Cox, as Co-Personal Representatives of
the Estate of Barbara Bobo, deceased, Plaintiffs v. Tennessee Valley Authority,
Defendant, United States District Court for the Northern District of Alabama,
Northeastern Division, 2015
Mary Lou Smith, Plaintiff and Appellant, v. Pneumo Abex LLC, Defendant and
Appellant, Court of Appeal of California, Second Appellate District, Division
Three, 2010

award for future medical expense in addition to past medical expense.
exposure.
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Our study attempted to determine average treatment
costs for a typical patient with mesothelioma in the United
States. We considered a health system perspective, and did
not include indirect or intangible costs, which are important
to the patient and broader perspectives. In addition, we did
not attempt to adjust for cost inflation or specifically contrast cost estimates across countries, given the complexity
of accounting for differing health care systems and treatment standards. Moreover, we were unable to identify published information describing the cost of outpatient care for
mesothelioma in the United States.

Conclusion
Mesothelioma is a rare form of cancer having a very poor
prognosis. The cost burden of the disease to the US health
care system is limited due to its relatively low prevalence,
and data describing the average costs of care are lacking.
We estimated the total cost of inpatient care in the United
States to be US$41,709,687 for 2014. Additional research
is warranted to determine the total costs of treatment overall, including outpatient care, the cost of emerging medication therapies, and indirect and intangible costs.
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